Skip to main content
Premium Trial:

Request an Annual Quote

Akonni Receives $435K NIH Grant to Develop MTB Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Akonni Biosystems said today it has received a $435,000 grant to further develop its technology for the identification of a broad range of multi-drug resistant strains of Mycobacterium tuberculosis.

The grant from the National Institutes of Biomedical Imaging and Bioengineering at the National Institutes of Health will be used to accelerate development of Akonni's hands-free, sample-to-answer system with a goal of providing testing to underserved populations, Akonni said. In the US, a large disparity exists in the susceptibility to tuberculosis based on race and socioeconomic status, the Frederick, Md.-based firm said.

Akonni's test will be based on its TruArray gel-drop microarray technology, which gives the company the ability to investigate tens of thousands of genetic markers from a patient to identify the most common strains of MTB, said Akonni's Chris Cooney, the principal investigator on the grant.

Laboratorios Medicos Especializados in Juarez, Mexico, will collaborate with Akonni on the program to assess and verify the point-of-care prototype system.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.